CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
BioTheranostics’ Prostate Cancer Index is a strong predictor of prostate cancer recurrence and may improve upon the current standard of care for assessing risk of recurrence and metastasis in patients with prostate cancer, according to a study published online in the Proceedings of the National Academy of Sciences (doi:10.1073/pnas.1215870110. Epub March 26, 2013).
The Prostate Cancer Index (PCI), now in development, is a 32-gene signature designed to predict prostate-specific antigen recurrence. In the study, conducted in collaboration with Massachusetts General Hospital, the PCI was validated in an independent, blinded set of 270 radical prostatectomy tumor samples. Results showed that the PCI was prognostic for risk of PSA recurrence and had added value over standard clinical prognostic markers such as Gleason score, pathologic tumor stage, surgical margin status, and pre-surgery PSA levels (P=0.0057). Surgical margin status was the only other factor with significant prognostic value.
The study also showed that the PCI could stratify patients based on the risk of PSA recurrence and the development of metastatic disease. The categories defined by the index significantly stratified patients based on risk of metastasis: the 10-year probability of metastasis was 14 percent in the high-risk group, and zero percent in the low-risk group (P=0.0006).
BioTheranostics, 877-886-6739